Neubase Therapeutics Stock Alpha and Beta Analysis
NBSE Stock | USD 0.41 0.01 2.38% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as NeuBase Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in NeuBase Therapeutics over a specified time horizon. Remember, high NeuBase Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to NeuBase Therapeutics' market risk premium analysis include:
Beta (1.97) | Alpha (0.27) | Risk 8.45 | Sharpe Ratio (0.04) | Expected Return (0.35) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
NeuBase |
NeuBase Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. NeuBase Therapeutics market risk premium is the additional return an investor will receive from holding NeuBase Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in NeuBase Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate NeuBase Therapeutics' performance over market.α | -0.27 | β | -1.97 |
NeuBase Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of NeuBase Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how NeuBase Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.NeuBase Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how NeuBase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading NeuBase Therapeutics shares will generate the highest return on investment. By understating and applying NeuBase Therapeutics stock market price indicators, traders can identify NeuBase Therapeutics position entry and exit signals to maximize returns.
NeuBase Therapeutics Return and Market Media
The median price of NeuBase Therapeutics for the period between Wed, Feb 7, 2024 and Tue, May 7, 2024 is 0.68 with a coefficient of variation of 34.56. The daily time series for the period is distributed with a sample standard deviation of 0.23, arithmetic mean of 0.66, and mean deviation of 0.2. The Stock received some media coverage during the period. Price Growth (%) |
Timeline |
1 | Disposition of tradable shares by Symetryx Corp of NeuBase Therapeutics subject to Rule 16b-3 | 03/22/2024 |
2 | Insider Trading | 03/25/2024 |
3 | Why Neubase Therapeutics Shares Are Nosediving | 03/26/2024 |
4 | NeuBase faces Nasdaq delisting over late annual report | 04/05/2024 |
5 | SYMETRYX CORPORATION ACQUIRES 20 percent STOCK IN NEUBASE - Barchart | 04/24/2024 |
About NeuBase Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including NeuBase or other stocks. Alpha measures the amount that position in NeuBase Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
NeuBase Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of NeuBase Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeuBase Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of NeuBase Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of NeuBase Therapeutics. Please utilize our Beneish M Score to check the likelihood of NeuBase Therapeutics' management manipulating its earnings.
13th of February 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
30th of September 2023 Last Quarter Report | View |
Build Portfolio with NeuBase Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out NeuBase Therapeutics Backtesting, NeuBase Therapeutics Valuation, NeuBase Therapeutics Correlation, NeuBase Therapeutics Hype Analysis, NeuBase Therapeutics Volatility, NeuBase Therapeutics History and analyze NeuBase Therapeutics Performance. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
NeuBase Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.